The recent type 2 diabetes drug empagliflozin in complex with the sodium-coupled glucose transporter SGLT2, demonstrates how selective inhibition was achieved by the aglycone of the glucoside inhibitor interacting with the mobile TM1a-b and TM6a-b half-helices (Niu et al., 2022). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.